At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 12 enrolled
Drug / intervention
Paliperidone ERdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 2 Fixed Dosages of Paliperidone Extended Release Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·interventional·Posted Feb 16, 2004·Updated Jun 8, 2011
In Brief
A Phase 3 clinical trial evaluating Paliperidone ER for Schizophrenia. Completed, enrolled 12 participants.
Detailed Summary
The purpose of this trial is to determine if paliperidone ER is an effective treatment for adults with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2004
First PostedFeb 2004
Study CompletionJan 2005
TodayJul 2026
First PostedFeb 16, 2004
Enrollment StartJan 1, 2004
Study CompletionJan 1, 2005
TodayJul 2, 2026
Posted 22.4 years ago
Interventions
Paliperidone ERdrug